stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Return on invested capital
Immunome, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −3,323.0%, down 3323.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −503.3% (fiscal 2019) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 368.60 |
| FY2020 | −368.6% | 134.71 |
| FY2019 | −503.3% | (246.17) |
| FY2018 | −257.1% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ADMA ADMA Biologics Inc compare | 48.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 43.0% |
| VCEL Vericel Corporation compare | 7.88% |
| CLDX Celldex Therapeutics, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| IMNM Immunome, Inc. | −3,323.0% |
| BHVN Biohaven Ltd. compare | −6,659.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement